VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

May 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-04-28

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-28	Common Stock	M	28320	$45.11	Acquired	159567	Direct
2017-04-28	Common Stock	S	28320	$119.50	Disposed	131247	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-04-28	Stock Option (Right to Buy)	$45.11	M	28320	Disposed	2023-02-04	Common Stock (28320)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: Fully vested.